RPL17 and cancer: In several canine cancers, the immune checkpoint programmed death-1 (PD-1) and its ligand PD-ligand 1 (PD-L1) were recently suggested as prognostic markers as well as promising therapeutic targets [21,22,23,24,25,26,27].